Ra Medical Systems (NYSE:RMED) today announced an increase in clinical adoption for its VIVO system across hospitals.
The product line falls within Ra Medical’s electrophysiology division, called Catheter Precision. Catheter Precision recently expanded its sales and clinical support team in the U.S. as part of a full product launch for VIVO. Earlier this month, Ra Medical also began to expand its distribution channels outside the U.S.
VIVO (view into ventricular onset) is a 3D, noninvasive mapping system. It enables physicians to identify the origin of ventricular arrhythmias pre-procedure. This streamlines workflows and reduces procedure time. Ra Medical’s Catheter Precision division received both FDA clearance and CE mark approval for VIVO.
Patricia Kennedy, chief commercial officer at Catheter Precision, said VIVO remains under review with “several notable accounts.” Kennedy added that hospitals increasingly leverage technology to reduce costs, save time and improve patient outcomes. The company expects approvals in the coming months in the U.S.
Included in the evaluations over the next few weeks are a number of hospitals, including Staten Island University Hospital, Wellspan Hospital in York, Pennsylvania, Our Lady of the Lake Hospital in Baton Rouge, Louisiana, Valley Hospital in Ridgewood, New Jersey, and Cleveland Clinic Akron, as well as Cleveland Clinic, main campus in Cleveland, Ohio.
“Clinical adoption and utilization are a critical part of our growth strategy,” said David Jenkins, Ra Medical interim CEO. “Not every product is approved for evaluation, and receiving approval means that the physicians and hospital staff see value in a product, and the evaluation provides us the opportunity to demonstrate these values. Customers are recognizing the values and increasing their utilization of VIVO as evidenced by the increased orders in the consumable accessories.”
